Overview

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD)

Status:
Not yet recruiting
Trial end date:
2025-08-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subjects.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen